Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.

Mult Scler Relat Disord

University Hospital Center Zagreb, Department of Neurology, Referral Center for Autonomic Nervous System Disorders, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. Electronic address:

Published: November 2020

Alemtuzumab is a humanized monoclonal antibody targeting CD52 protein that has shown great efficacy in the treatment of relapsing remitting multiple sclerosis and is associated with prolonged remission of the disease. Although it is highly effective, alemtuzumab can lead to serious adverse advents among which the most common are secondary autoimmune diseases. We present a patient who was treated with alemtuzumab for relapsing remitting multiple sclerosis. Her disease remained stable in a follow-up period of over ten years. However, during the follow-up period she developed thyroiditis one year, as well as systemic erythematous lupus seven years after the last alemtuzumab infusion, a disease not previously associated with alemtuzumab administration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2020.102589DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
12
systemic erythematous
8
erythematous lupus
8
relapsing remitting
8
remitting multiple
8
follow-up period
8
alemtuzumab
6
lupus treatment
4
treatment multiple
4
sclerosis alemtuzumab
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!